Gilead Sciences, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $7.56B | $9.99B | $6.09B | $5.41B | $5.34B | $6.00B | $11.63B | $17.94B |
| Accounts Receivable | $4.91B | $4.42B | $4.66B | $4.78B | $4.49B | $4.89B | $3.58B | $3.33B |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | $1.62B | $1.68B | $922.0M | $814.0M |
| Total Current Assets | $18.34B | $19.17B | $16.09B | $14.44B | $14.77B | $16.00B | $30.30B | $35.84B |
| Property, Plant & Equipment | $5.61B | $5.41B | $5.32B | $5.48B | $5.12B | $4.97B | $4.50B | $4.01B |
| Goodwill | $8.31B | $8.31B | $8.31B | $8.31B | $8.33B | $8.11B | $4.12B | $4.12B |
| Intangible Assets (Excl. Goodwill) | $16.98B | $19.95B | $26.45B | $28.89B | $33.46B | $33.13B | $13.79B | $15.74B |
| Total Assets | $59.02B | $59.00B | $62.13B | $63.17B | $67.95B | $68.41B | $61.63B | $63.68B |
| Liabilities | ||||||||
| Accounts Payable | $715.0M | $833.0M | $550.0M | $905.0M | $705.0M | $844.0M | $713.0M | $790.0M |
| Total Current Liabilities | $11.81B | $12.00B | $11.28B | $11.24B | $11.61B | $11.40B | $9.76B | $10.61B |
| Long-Term Debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B | $28.65B | $22.09B | $24.57B |
| Total Liabilities | $36.32B | $39.67B | $39.29B | $41.93B | $46.88B | $50.21B | $39.10B | $42.29B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $13.73B | $11.50B | $16.30B | $15.69B | $16.32B | $14.38B | $19.39B | $19.02B |
| Total Stockholders' Equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B | $18.20B | $22.53B | $21.39B |